hotspot -WSS

hotspot

author：comprehensive 2025-09-06 02:13:33 - browse：9

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： What we need to know about Arena Bioworks

entertainment

WSS

How doctors and nurses shape Google's AI

SAMSHA loosens regulations on methadone treatment centers

Eight reasons why you should get an updated Covid vaccine

Cognito secures funding to test medical device for Alzheimer's

Covid misinformation case heads to Supreme Court

Cognito secures funding to test medical device for Alzheimer's

hotspot

hotspot

Wikipedia

Sports medicine is finally prioritizing gender equality

How clinical AI models' predictive power can degrade over time

As demand for Covid shots wanes, Moderna seeks its next success

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Medical leaders decry Supreme Court decision on affirmative action

Commercial surrogacy can be ethical, despite pope’s claims

Peter Hotez and the public health issue of online harassment

General Catalyst, Summa Health deal will turn on physician buy

After affirmative action ruling, medical educators look to 'holistic review'

There’s no way to know how good AI health technologies are

explore

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Takeaways from AdvaMed, the largest medical devices conference

Apple Vision Pro: A first look at health apps on the new VR headset

Readout LOUD podcast: Merger Mondays, Ozempic panic

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Life sciences deals on track to hit lowest point since 2017

entertainment

focus

entertainment

Wikipedia